1. Scrip

Phathom’s First Approval Of Voquezna Expected To Lay Ground For Larger Indications

 
• By Joseph Haas

The Takeda spinout got FDA approval of its acid blocker as combination therapy for H. pylori infections, but the bigger opportunities await in erosive esophagitis and non-erosive reflux disorder.

H pyloria bacteria
Phathom hopes Voquezna will improve the standard of care for H. pylori infections • Source: Alamy

Takeda Pharmaceutical Co. Ltd. spinout Phathom Pharmaceuticals, Inc. got its first US Food and Drug Administration approval, for the acid-blocker vonoprazan, on 3 May, which could be a precursor to future approvals in gastroesophageal reflux disorder (GERD) indications that may give the drug blockbuster sales in the US. The initial approval is for Voquezna Triple Pak and Voquezna Dual Pak, for treating Heliobacter pylori infections, consisting of vonoprazan packaged with generic antibiotics.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from New Products

More from Scrip

Japan Market Entry: Consortium’s One-Stop Shop To Support Foreign Entrants

 
• By Lisa Takagi

Japanese CDMO Bushu talks about a consortium designed to provide a broad range of development services to smaller foreign firms looking to bring high-need drugs to the Japanese market.

Bristol’s Growth Plans Take A Hit As Cobenfy Fails As A Schizophrenia Add-On

 
• By Mandy Jackson

Cobenfy is approved as a monotherapy, but failed in the adjunctive setting when combined with generic atypical antipsychotics, giving BMS a second Phase III failure in two weeks.

Data From China Bolster Summit/Akeso’s Case For Ivonescimab

 
• By Alaric DeArment

Results from the Phase III HARMONi-6 trial showed the PD-1/VEGF bispecific antibody beating out BeiGene’s Tevimbra in NSCLC.